In short
Clinical trials investigating Gonadotropin Releasing Hormone Analogues are studying treatment strategies for men with metastatic castration-sensitive prostate cancer. These trials look at whether different treatment plans can control the disease while also measuring safety, quality of life, and symptom burden such as hot flashes.
Key points
- One clinical trial is listed for Gonadotropin Releasing Hormone Analogues, and it studies men with metastatic castration-sensitive prostate cancer. This is a Phase 3 interventional trial with 521 planned participants. The study looks at an intermittent treatment approach after apalutamide and ADT combination therapy, in people who reached a PSA below 0.2 ng/mL. The main outcomes are 18-month radiographic progression-free survival and hot flash burden. The trial is authorised.
Trial overview
This article covers one authorised interventional study of Gonadotropin Releasing Hormone Analogues in men with metastatic castration-sensitive prostate cancer (mCSPC). The study is testing an intermittent androgen deprivation therapy (ADT) approach with apalutamide monotherapy after earlier combination treatment.
The trial asks whether the intermittent approach can keep cancer control similar while lowering the burden of hot flashes. The study is authorised and planned for 521 participants.
Who is being studied
The target population is participants with metastatic castration-sensitive prostate cancer, which means prostate cancer that has spread and still responds to hormone-based treatment. The brief summary also says participants must have reached a PSA level below 0.2 ng/mL after 6 months of apalutamide and ADT combination therapy.
PSA stands for prostate-specific antigen, a blood marker used to follow prostate cancer activity. This means the study is focused on people whose disease responded well enough to earlier treatment to move into the next study step.
What is being measured
The main disease outcome is 18-month radiographic progression-free survival. Radiographic progression-free survival means the time during which scans do not show the cancer getting worse.
The study also measures the 18-month percent change in severity adjusted hot flash score. This score tracks how often hot flashes happen and how strong they are, so the trial can measure symptom burden as well as cancer control.
Trial phase and design
This is a Phase 3 trial. Phase 3 studies usually involve larger groups and are used to compare how well a treatment strategy works in real clinical research settings.
The study type is interventional, which means the researchers assign a treatment plan and then measure the results. In this trial, the plan includes intermittent ADT with apalutamide monotherapy, compared with the study’s main outcome goals.
What this means for patients
For patients, this trial is mainly about finding a treatment pattern that may keep prostate cancer under control while reducing treatment burden. The focus is not only on scan results, but also on day-to-day effects such as hot flashes.
Because only one trial is listed in the source data, the current picture is limited to this specific study in mCSPC. The available data do not provide extra details about other cancer types, other phases, or additional trial endpoints beyond the ones listed here.